Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Isoliquiritigenin, pharmaceutical composition and application thereof in treatment of diabetic nephropathy

A technology for diabetic nephropathy and isoliquiritigenin, which is applied to isoliquiritigenin, pharmaceutical compositions and their application fields in the treatment of diabetic nephropathy, can solve problems such as immature development and application, and achieves delaying disease progression and deterioration, low cost, Efficacy of alleviating onset and progression

Pending Publication Date: 2019-03-19
THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, isoliquiritigenin is often used in cosmetics and food additives, and it is still immature for development and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isoliquiritigenin, pharmaceutical composition and application thereof in treatment of diabetic nephropathy
  • Isoliquiritigenin, pharmaceutical composition and application thereof in treatment of diabetic nephropathy
  • Isoliquiritigenin, pharmaceutical composition and application thereof in treatment of diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0072] Effects of ISL on organ complications in STZ-induced type 1 diabetic mice

[0073] Male C57BL / 6 mice were obtained from the Animal Experiment Center of Wenzhou Medical University. Mice were housed in a thermostated 12-12h diurnal animal room with standard rodent chow and water. Animals underwent more than one week of environmental adaptation before the start of the experiment.

[0074] Male C57BL / 6 mice aged 8-10 weeks were randomly divided into 4 groups: normal control group (ctrl group), diabetes group (STZ-DM1 group), diabetes group combined with ISL (STZ-DM1+ISL group) treatment group (10 , 20mg / kg / d two doses), intragastric administration; every group of 8.

[0075] Low-dose 50mg / kg / d streptozotocin intraperitoneal injection, continuous injection for 5 days to build a type 1 diabetes model, 72 hours later, blood glucose meter to measure fasting blood glucose (fasting for 4-6 hours), blood glucose value ≥ 12mmol / L At that time, a mouse model of type 1 diabetes wa...

experiment example 2

[0085] The kidney tissue obtained in Experimental Example 1 was taken, and the inflammatory factors (TNF-α) and macrophage markers (F4 / 80) in the kidney tissue were detected by immunohistochemistry, and the concentration of reactive oxygen species (ROS) in the kidney was detected by DHE fluorescent dye. Produced and detected oxidative stress-related factor (3-NT) by immunohistochemistry. For experimental data, see image 3 with Figure 4 ,in,

[0086] image 3 Middle A is the effect picture of detecting the inflammatory factor TNF-α in kidney tissue by immunohistochemistry, and A' is the enlarged picture of the boxed part in A, Figure 4 B is image 3 The statistical graph of A. Depend on image 3 A, A' and Figure 4 B shows that ISL can significantly reduce the content of inflammatory factor TNF-α in kidney tissue of STZ-induced type 1 diabetic mice.

[0087] image 3 Middle C is the effect diagram of detecting macrophage markers (F4 / 80) in kidney tissue by immunohis...

experiment example 3

[0093] ISL can alleviate HG-induced renal cell inflammatory response

[0094] The in vitro anti-inflammatory activity of ISL was tested by inhibiting the release of inflammatory factors (TNF-α and IL-1β) and chemokine (MCP-1) in NRK-52E kidney cells stimulated by HG. The specific methods are as follows:

[0095] 1.2×10^6 NRK-52E kidney cells were cultured with DMEM medium at 37°C. After 24 hours, the medium was renewed and pretreated with ISL (final concentration of 10 and 20 μM) for 1 hour, and then treated with high glucose (HG 33mM Glucose) continued to be treated for 6 hours, and the culture fluid was collected to detect the mRNA expression levels of inflammatory factors TNF-α, IL-1β and MCP-1 by RT-qPCR method. Each compound was tested 3 times, and the average value and error value were calculated.

[0096] The in vitro anti-inflammatory and antioxidant activity of ISL was tested by using the method of ISL to inhibit the activation of inflammatory signaling pathway (MAPKs...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for improving inflammation and oxidative stress reaction. The composition contains isoglycyrrhizin. The invention further provides use of the isoglycyrrhizin in preparation of a drug for treating chronic inflammatory diseases and oxidative stress injury diseases and application of the isoglycyrrhizin in preparation of a drug for treating diabeticnephropathy. The isoliquiritin has no toxic and side effects in treating the diabetic nephropathy, is low in cost and high in combined drug administration safety, and contributes to delaying exacerbation.

Description

technical field [0001] The present invention relates to the therapeutic use of isoliquiritigenin or a pharmaceutical composition containing isoliquiritigenin in the treatment of organ damage caused by diabetes or hyperglycemia, in particular to the use of isoliquiritigenin in the preparation of medicines for treating kidney damage induced by diabetes or hyperglycemia . Background technique [0002] With the development of society, the prevalence of Diabetes Mellitus (DM) has increased significantly, and it has become an epidemic disease that affects human health. Diabetic nephropathy (Diabetic nephropathy, DN) is one of the main microvascular complications of diabetic patients, which ultimately leads to high mortality and disability in diabetes. The disease is caused by a decrease in glomerular filtration rate on the basis of metabolic disorders and microvascular lesions, followed by microalbuminuria, elevated arterial blood pressure, proteinuria, and fluid retention, event...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/12A61P3/10A61P13/12A61P29/00A61P39/06
CPCA61K31/12A61P3/10A61P13/12A61P29/00A61P39/06
Inventor 陈雄陈咨苗陈朝生施玉娟吴文俊叶婷婷刘文悦邓武权顾雪疆谷雪梅
Owner THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com